[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630376":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":45,"collaborators":48,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":19,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":19,"enrollmentInfo":61,"targetDuration":19,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":19,"overallStatus":76,"whyStopped":19,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University of Miami","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Emapalumab","EXPERIMENTAL","Participants will receive emapalumab administered intravenously at a dose of 6 mg\u002Fkg on Day 1, followed by 3 mg\u002Fkg every 3 days for 2 weeks, and then 3 mg\u002Fkg twice weekly for an additional 2 weeks. Total treatment duration is 12 weeks.",[13],"Drug: Emapalumab",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Emapalumab administered intravenously according to the following dosing regimen: 6 mg\u002Fkg on Day 1, followed by 3 mg\u002Fkg every 3 days for 2 weeks, and then 3 mg\u002Fkg twice weekly for 2 weeks.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Kelly Corbitt, D.O.","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","305-243-7545","KKC51@miami.edu",[30],{"facility":31,"status":19,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"University of Miami Hospital and Clinics","Miami","Florida","33136","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-80.19366,25.77427,{"lat":41,"lon":40},[44],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},{"type":23,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Kelly Corbitt","Assistant Professor of Clinical Medicine",[49],{"name":50,"class":51},"Swedish Orphan Biovitrum","INDUSTRY","100630376","phase-2-emapalumab-mda5-rapidly-progressive-interstitial-lung-disease-rp-ild-study-100630376",false,"NCT07486869","Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study","Emapalumab for the Treatment of Anti-MDA5 Antibody Positive Rapidly Progressive Interstitial Lung Disease","Inclusion Criteria:\n\n* Progressive interstitial lung disease as determined by at least 2\u002F4 of the following:\n\n  1. worsening respiratory symptoms;\n  2. worsening or new oxygen requirement;\n  3. worsening disease on CT chest;\n  4. worsening Forced Vital Capacity (FVC1) or Diffusing Capacity for Carbon Monoxide (DLCO) on pulmonary function tests\n* MDA5 antibodies present\n* Elevated ferritin above the upper limit of normal (ULN)\n* Participant at least 18 years old\n\nExclusion Criteria:\n\n* Active, untreated bacterial, mycobacterial or fungal infection\n* Active herpes zoster infection\n* Currently requiring extracorporeal membrane oxygenation (ECMO)\n* Participant refusal to participate in the study\n* Pregnant women\n* Prisoners","ALL","18 Years",{"count":62,"type":63},5,"ESTIMATED","INTERVENTIONAL",[66],"PHASE2","This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage activation syndrome, and this disease shares some similar features with MDA5 RP-ILD.",[69,70,71,72,73,74,75],"Dermatomyositis","Dermatomyositis Sine Myositis","Dermatomyositis With Myopathy","Dermatomyositis With Respiratory Involvement","Dermatomyositis With Organ Involvement","Interstitial Lung Disease","Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)","NOT_YET_RECRUITING","2026-06-16",{"date":79,"type":80},"2026-06-18","ACTUAL",{"date":82,"type":63},"2026-07",{"date":84,"type":63},"2027-05",{"name":5,"class":6},1]